Patients enrolled in Prolastin Direct experienced 10% fewer exacerbations.1Exacerbation Reduction Graph

Prolastin Direct Alpha-1 health management program helps improve patient outcomes.

  • Total exacerbation rate decreased (P<0.001)
  • Unscheduled physician visits decreased (P=0.03)
  • Emergency room visits decreased (P=0.02)

Learn more about Alpha-1 Disease Management and Prevention Program (ADMAPP).

PROLASTIN-C Therapy - You get more than just a product.

Demonstrated efficacy

  • Since 1988 Prolastin has been shown to raise AAT levels in as little as 1 month1.
  • In clinical trials, PROLASTIN-C was as effective as PROLASTIN at raising AAT levels1.

In clinical trials

  • The most serious adverse reaction observed during clinical studies with Prolastin-C was an abdominal and extremity rash in one subject.
  • The most common drug-related adverse reactions observed at a rate of ≥ 1% were chills, malaise, headache, rash, hot flush and pruritus.

The effect of augmentation therapy with any alpha1-proteinase inhibitor (Alpha-1-PI) on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.

Higher purity

Each dose of Prolastin-C delivers ≥90% pure alpha-1 protein allowing it to be more concentrated than Prolastin

Patient conveniences

  • Shorter infusion volume and time compared to PROLASTIN
  • average 15-minute infusion time when given at the recommended infusion rate
  • Easy product storage
  • no refrigeration needed

PROLASTIN DIRECT Alpha-1 health management program helps improve patient outcomes.1

Patients benefit when alpha-1 health management is added to therapy.

Direct Process Flow

Enroll your Alphas in Prolastin Direct Patient Services® now

Enrolling your patients is simple, fill out the prescription and enrollment form.

next: Dosage & Administration of PROLASTIN-C >

Important Safety Information

PROLASTIN-C, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic augmentation and maintenance therapy in adults with emphysema due to deficiency of alpha1-proteinase inhibitor (alpha1-antitrypsin deficiency). The effect of augmentation therapy with any alpha1-proteinase inhibitor (alpha1-PI) on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials. PROLASTIN-C is not indicated as therapy for lung disease in patients in whom severe Alpha1-PI deficiency has not been established.

PROLASTIN-C may contain trace amounts of IgA. Patients with known antibodies to IgA, which can be present in patients with selective or severe IgA deficiency, have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. PROLASTIN-C is contraindicated in patients with antibodies against IgA.

The most common drug related adverse reactions during clinical trials in ≥ 1% of subjects were chills, malaise, headache, rash, hot flush, and pruritus.

PROLASTIN-C is made from human plasma. Products made from human plasma may carry a risk of transmitting infectious agents, e.g., viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Please see accompanying PROLASTIN-C Full Prescribing Information for complete prescribing details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

References
  1. Campos MA, Alazemi S, Zhang G, Wanner A, Sandhaus RA. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. COPD. 2009;6(1):31-40.
  2. PROLASTIN-C [package insert]. Grifols.